Anacetrapib
Review asks whether JTT-705 (dalcetrapib) or anacetrapib can still succeed after the collapse of torcetrapib (Expert Opin Investig Drugs 2008)
Original title: JTT-705: is there still future for a CETP inhibitor after torcetrapib?
Despite LDL cholesterol reduction, considerable residual atherosclerosis-related disease persists, and epidemiological and pathophysiological evidence favors raising HDL cholesterol, including through CETP inhibition, as antiatherogenic therapy. However, the negative phase III clinical endpoint results for the CETP inhibitor torcetrapib called into question the prospects of other CETP inhibitors such as JTT-705 (dalcetrapib). Based on a PubMed literature search of articles citing JTT-705, torcetrapib, and anacetrapib, or discussing pharmacological HDL-cholesterol raising or CETP inhibition, the authors conclude that a future for HDL-cholesterol-raising therapies remains possible, and that ongoing phase III studies of JTT-705 or anacetrapib will ultimately determine whether CETP inhibition as a class delivers clinical benefit.
Original abstract
Background: Despite reduction in low-density lipoprotein cholesterol, there is still a considerable amount of residual atherosclerosis-related disease. Epidemiological and pathophysiological data strongly favour increasing plasma high-density lipoprotein (HDL) cholesterol levels as antiatherogenic therapy, for example with cholesteryl ester transfer inhibition (CETP). However, negative Phase III studies on clinical end points with the CETP inhibitor torcetrapib challenge the future perspectives of other CETP inhibitors such as JTT-705.
Objective: Is there potential for CETP inhibition with JTT-705 after torcetrapib's collapse?
Methods: Search of articles in Pubmed citing JTT-705, torcetrapib and anacetrapib, or citing effects of pharmacological HDL-cholesterol raising or CETP inhibition.
Results/Conclusion: There is possibly a future for HDL-cholesterol raising therapies. Phase III clinical studies with either JTT-705 or anacetrapib will determine whether CETP inhibition is beneficial.
anacetrapibthe classdalcetrapib
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.